Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aclaris Therapts (NQ: ACRS )

1.160 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 323,499
Open 1.170
Bid (Size) 1.160 (419)
Ask (Size) 1.170 (106)
Prev. Close 1.160
Today's Range 1.150 - 1.179
52wk Range 0.5902 - 6.980
Shares Outstanding 71,344,557
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices. 
Via MarketBeat

Performance

YTD
+10.48%
+10.48%
1 Month
-4.92%
-4.92%
3 Month
-10.08%
-10.08%
6 Month
N/A
N/A
1 Year
-82.32%
-82.32%

More News

Read More
Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying
Via Benzinga
$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Aclaris Therapeutics: Q4 Earnings Insights
Via Benzinga
The Analyst Landscape: 4 Takes On Aclaris Therapeutics
Via Benzinga
Breaking Down Aclaris Therapeutics: 6 Analysts Share Their Views
Via Benzinga
ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
Via FinancialNewsMedia
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
Via Benzinga
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?
Via Benzinga
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Via Benzinga
Crude Oil Falls 1%; Amarin Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Gains 50 Points; US Crude Inventories Rise Last Week
Via Benzinga
Topics Stocks
Exposures US Equities
Aclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema Trial
Via Benzinga
Dow Surges 100 Points; PriceSmart Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Inflammatory Disease Focused Aclaris Therapeutics Reduces Staff After Failed Psoriatic Arthritis Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.